Denali Therapeutics Inc. (DNLI) · Insider trading
What Denali Therapeutics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$1.30M
4 insiders, 25% under a plan
Net, 12 months
−$1.30M
bought less sold
Latest filing
2026-09-09
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Watts Ryan J.Director, President and CEO | – | $8.76M | 4 | 2026-01-06 | 296,833 |
| Schenkein David PDirector | – | $1.93M | 2 | 2024-11-11 | 41,532 |
| Schuth Alexander O.COFO and Secretary | – | $1.23M | 9 | 2026-09-01 | 278,995 |
| Krognes Steve E.Director | – | $676,985 | 2 | 2025-01-07 | 25,757 |
| Ho CaroleChief Medical Officer | – | $359,975 | 4 | 2025-08-13 | 216,585 |
| Thornberry NancyDirector | – | $261,929 | 2 | 2026-09-02 | 20,301 |
| Sato Vicki LDirector | – | $178,378 | 3 | 2025-01-02 | 107,976 |
| Chin Peter ScottChief Medical Officer | – | $36,868 | 1 | 2026-09-04 | 204,538 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Chin Peter ScottChief Medical Officer | Sale | 1,654 | 22.29 | $36,868 | 204,538 | Form 4 |
| 2026-09-02 | Thornberry NancyDirector | Saleplan | 10,824 | 22.85 | $247,328 | 20,301 | Form 4 |
| 2026-09-02 | Thornberry NancyDirector | Saleplan | 615 | 23.74 | $14,600 | 19,686 | Form 4 |
| 2026-09-01 | Schuth Alexander O.COFO and Secretary | Saleplan | 2,768 | 23.44 | $64,882 | 278,995 | Form 4 |
| 2026-08-11 | Schuth Alexander O.COFO and Secretary | Sale | 2,857 | 25.07 | $71,625 | 281,763 | Form 4 |
| 2026-01-06 | Watts Ryan J.Director, President and CEO | Sale | 35,198 | 16.50 | $580,767 | 296,833 | Form 4 |
| 2026-01-06 | Schuth Alexander O.COFO and Secretary | Sale | 17,218 | 16.50 | $284,097 | 282,828 | Form 4 |
| 2025-08-13 | Ho CaroleChief Medical Officer | Saleplan | 806 | 14.64 | $11,800 | 216,585 | Form 4 |
| 2025-08-12 | Ho CaroleChief Medical Officer | Saleplan | 2,937 | 13.58 | $39,884 | 217,391 | Form 4 |
| 2025-08-12 | Schuth Alexander O.COFO and Secretary | Sale | 2,937 | 13.58 | $39,884 | 242,346 | Form 4 |
| 2025-07-09 | Watts Ryan J.Director, President and CEO | Saleplan | 495,282 | 15.00 | $7.43M | 253,071 | Form 4 |
| 2025-01-07 | Krognes Steve E.Director | Sale | 3,339 | 20.81 | $69,485 | 25,757 | Form 4 |
| 2025-01-07 | Watts Ryan J.Director, President and CEO | Sale | 7,650 | 20.81 | $159,196 | 253,071 | Form 4 |
| 2025-01-07 | Schuth Alexander O.COFO and Secretary | Sale | 2,907 | 20.81 | $60,495 | 244,308 | Form 4 |
| 2025-01-07 | Ho CaroleChief Medical Officer | Sale | 2,907 | 20.81 | $60,495 | 175,673 | Form 4 |
| 2025-01-06 | Watts Ryan J.Director, President and CEO | Sale | 29,266 | 20.22 | $591,759 | 260,721 | Form 4 |
| 2025-01-06 | Schuth Alexander O.COFO and Secretary | Sale | 12,255 | 20.22 | $247,796 | 247,215 | Form 4 |
| 2025-01-06 | Ho CaroleChief Medical Officer | Sale | 12,255 | 20.22 | $247,796 | 178,580 | Form 4 |
| 2025-01-02 | Sato Vicki LDirector | Saleplan | 3,080 | 20.91 | $64,403 | 107,976 | Form 4 |
| 2024-12-31 | Krognes Steve E.Director | Saleplan | 30,000 | 20.25 | $607,500 | 29,096 | Form 4 |
| 2024-11-11 | Schenkein David PDirector | Saleplan | 27,129 | 32.09 | $870,570 | 41,532 | Form 4 |
| 2024-11-11 | Schenkein David PDirector | Saleplan | 32,312 | 32.87 | $1.06M | 9,220 | Form 4 |
| 2024-11-07 | Sato Vicki LDirector | Saleplan | 1,020 | 30.00 | $30,600 | 111,056 | Form 4 |
| 2024-11-07 | Schuth Alexander O.COFO and Secretary | Saleplan | 12,333 | 29.68 | $366,043 | 181,291 | Form 4 |
| 2024-11-07 | Schuth Alexander O.COFO and Secretary | Saleplan | 2,925 | 30.72 | $89,856 | 178,366 | Form 4 |
| 2024-11-07 | Schuth Alexander O.COFO and Secretary | Saleplan | 300 | 31.29 | $9,387 | 178,066 | Form 4 |
| 2024-11-01 | Sato Vicki LDirector | Saleplan | 3,080 | 27.07 | $83,376 | 112,076 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
24 × grant or award8 × option exercise2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-12 | Watts Ryan J.Director, President and CEO | Gift G | −32,220 | – | 2,120,384 | Form 4 |
| 2026-06-03 | Flatley Jay TDirector | Grant or award A | +6,408 | – | 22,628 | Form 4 |
| 2026-06-03 | Baker JulianDirector | Grant or award A | +6,408 | – | 343,275 | Form 4 |
| 2026-06-03 | Baker JulianDirector | Grant or award A | +6,408 | – | 3,422,366 | Form 4 |
| 2026-06-03 | Klein Peter SDirector | Grant or award A | +6,408 | – | 33,941 | Form 4 |
| 2026-06-03 | Schenkein David PDirector | Grant or award A | +6,408 | – | 21,665 | Form 4 |
| 2026-06-03 | Krognes Steve E.Director | Grant or award A | +6,408 | – | 38,202 | Form 4 |
| 2026-06-03 | Cook Jennifer E.Director | Grant or award A | +6,408 | – | 32,483 | Form 4 |
| 2026-06-03 | Thornberry NancyDirector | Grant or award A | +6,408 | – | 31,125 | Form 4 |
| 2026-06-03 | Van Hauwermeiren TimothyDirector | Grant or award A | +6,408 | – | 17,040 | Form 4 |
| 2026-01-03 | Watts Ryan J.Director, President and CEO | Grant or award A | +78,960 | – | 332,031 | Form 4 |
| 2026-01-03 | Schuth Alexander O.COFO and Secretary | Grant or award A | +57,700 | – | 300,046 | Form 4 |
| 2025-11-04 | Van Hauwermeiren TimothyDirector | Grant or award A | +10,632 | – | 10,632 | Form 4 |
| 2025-09-03 | Watts Ryan J.Director, President and CEO | Gift G | −50,000 | – | 2,152,604 | Form 4 |
| 2025-08-05 | Ho CaroleChief Medical Officer | Option exercise M | +44,655 | 0.68 | 220,328 | Form 4 |
| 2025-07-09 | Watts Ryan J.Director, President and CEO | Option exercise M | +455,282 | 0.68 | 708,353 | Form 4 |
| 2025-07-09 | Watts Ryan J.Director, President and CEO | Option exercise M | +40,000 | 5.28 | 748,353 | Form 4 |
| 2025-06-03 | Baker JulianDirector | Grant or award A | +10,565 | – | 336,867 | Form 4 |
| 2025-06-03 | Baker JulianDirector | Grant or award A | +10,565 | – | 3,415,958 | Form 4 |
| 2025-06-03 | Tessier-Lavigne MarcDirector | Grant or award A | +6,037 | – | 1,886,576 | Form 4 |
| 2025-06-03 | Thornberry NancyDirector | Grant or award A | +6,037 | – | 24,717 | Form 4 |
| 2025-06-03 | Schenkein David PDirector | Grant or award A | +6,037 | – | 15,257 | Form 4 |
| 2025-06-03 | Krognes Steve E.Director | Grant or award A | +6,037 | – | 31,794 | Form 4 |
| 2025-06-03 | Klein Peter SDirector | Grant or award A | +6,037 | – | 27,533 | Form 4 |
| 2025-06-03 | Flatley Jay TDirector | Grant or award A | +6,037 | – | 16,220 | Form 4 |
| 2025-06-03 | Cook Jennifer E.Director | Grant or award A | +6,037 | – | 26,075 | Form 4 |
| 2025-01-03 | Ho CaroleChief Medical Officer | Grant or award A | +54,180 | – | 190,835 | Form 4 |
| 2025-01-03 | Schuth Alexander O.COFO and Secretary | Grant or award A | +54,180 | – | 259,470 | Form 4 |
| 2025-01-03 | Watts Ryan J.Director, President and CEO | Grant or award A | +54,180 | – | 289,987 | Form 4 |
| 2024-12-27 | Schuth Alexander O.COFO and Secretary | Option exercise M | +6,708 | 5.28 | 205,290 | Form 4 |
| 2024-11-25 | Ho CaroleChief Medical Officer | Option exercise M | +17,845 | 0.68 | 136,655 | Form 4 |
| 2024-11-22 | Schuth Alexander O.COFO and Secretary | Option exercise M | +20,516 | 0.68 | 198,582 | Form 4 |
| 2024-11-11 | Schenkein David PDirector | Option exercise M | +47,165 | 18.00 | 68,661 | Form 4 |
| 2024-11-07 | Schuth Alexander O.COFO and Secretary | Option exercise M | +15,558 | 5.28 | 193,624 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.